Aeterna Zentaris spikes as FDA accepts NDA for filing

|By:, SA News Editor

The FDA accepts Aeterna Zentaris' (AEZS +4.1%) NDA for macimorelin acetate in AGHD for filing.

The application was submitted in November.

Approval would make macimorelin acetate the "the first orally-administered product that induces growth hormone release to evaluate AGHD."

PDUFA date: November 5, 2014. (PR)